Yesterday, Bioheart, Inc. announced that it had acquired exclusive worldwide rights to adipose cell technology from Ageless Regenerative Institute, LLC. Adipose tissue is fat-based and has been shown to be rich in microvascular, myogenic, and angiogenic cells, which makes it the perfect candidate for use in the cardiac field.
Bioheart is focused on the cardiovascular sector of the cell technology industry with the development and commercialization of autologous cell therapies (pending approval). The company is specifically targeting their concentration in areas such as congestive heart failure, lower limb ischemia, chronic heart ischemia, and acute myocardial infarctions, among others. The company's flagship product, MyoCell, helps to repair areas of scar tissue in patient hearts with living cells.
According to the terms of the contract with Ageless, Bioheart will maintain an exclusive worldwide license to all of Ageless technology for use in the heart attack and heart failure markets, with upfront and milestone equity payments to Ageless.
Bioheart has applied to the FDA to commence trials that will use LipiCell (adipose-derived stem cells). This will be accomplished with endocardial implantations, using the MyoStar™ Injection Catheter. This process will be under the guidance of the NOGA® cardiac navigation system, developed by Biosense Webster, Inc.
Mike Tomas, president and CEO of Bioheart, said, "The Ageless adipose stem cell technology will allow us to broaden our portfolio of product candidates for cardiac patients. We have successfully treated patients in Mexico and now we are ready to expand into the US."
Sharon McQuillan, Ageless' president and CEO, added, "We are excited about this collaboration with Bioheart, a leader in developing cell therapies for cardiovascular disease. Together with Bioheart, we can help to revolutionize cardiovascular medicine and improve the current standard of care for these patients."
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net